Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.
Industry, Sector and Symbol
Industry Industrial inorganic chemicals
Sub-IndustryN/A
SectorMedical
Phone416-755-2231
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.28 million
Profitability
Miscellaneous
Employees23
OptionableNot Optionable
Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions
What is Polydex Pharmaceuticals' stock symbol?
Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."
When is Polydex Pharmaceuticals' next earnings date?
Has Polydex Pharmaceuticals been receiving favorable news coverage?
Media headlines about POLXF stock have trended positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Polydex Pharmaceuticals earned a news impact score of 2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the near future.
Who are some of Polydex Pharmaceuticals' key competitors?
Some companies that are related to Polydex Pharmaceuticals include Linde (LIN), Air Products & Chemicals (APD), JSR CORP/ADR (JSCPY), Minerals Technologies (MTX), Kronos Worldwide (KRO), Valhi (VHI), Tronox (TROX), Luxfer (LXFR), Venator Materials (VNTR), NL Industries (NL), LSB Industries (LXU), Hydrogenics (HYGS) and Praxair (PX).
Who are Polydex Pharmaceuticals' key executives?
Polydex Pharmaceuticals' management team includes the folowing people:
- Mr. George G. Usher, Chairman, CEO & Pres (Age 60)
- Mr. John Alfred Luce, CFO & Principal Accounting Officer (Age 72)
- Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 66)
How do I buy shares of Polydex Pharmaceuticals?
Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Polydex Pharmaceuticals' stock price today?
One share of POLXF stock can currently be purchased for approximately $0.93.
How big of a company is Polydex Pharmaceuticals?
Polydex Pharmaceuticals has a market capitalization of $3.14 million and generates $5.28 million in revenue each year. Polydex Pharmaceuticals employs 23 workers across the globe.
What is Polydex Pharmaceuticals' official website?
How can I contact Polydex Pharmaceuticals?
Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231 or via email at [email protected]
MarketBeat Community Rating for Polydex Pharmaceuticals (OTCMKTS POLXF)
MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote "Outperform" if you believe POLXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
